WO2020036555A2

WO2020036555A2 - An alkaline dialysate

Info

Publication number: WO2020036555A2
Application number: PCT/TR2019/050288
Authority: WO
Inventors: Emin ZUMRUTDAL
Original assignee: Individual
Current assignee: Individual
Priority date: 2018-05-02
Filing date: 2019-04-30
Publication date: 2020-02-20
Anticipated expiration: 2020-11-02
Also published as: WO2020036555A3

Abstract

Alkaline dialysate fluid is involved in preventing cancer cells from spreading during or after surgery of cancerous tissues, and in destroying cancer cells present in surrounding tissues. Alkaline dialysate fluid is associated with a positive contribution to the healing of traumatized tissues. Alkaline dialysate fluid relates to the acceleration of wound healing in infected tissues. It relates to alkaline dialyzing fluid used to increase tissue compatibility in implants to be implanted in the body. It is related to alkaline dialysate fluid used as dialysis fluid in chronic renal failure.

Description

AN ALKALINE DIALYSATE

TECHNICAL FIELD

The invention relates to alkaline dialysate fluid, which helps prevent cancer cells from spreading and destroy existing cancer cells in surrounding tissues, which contributes to wound healing positively, and which is created as dialysis fluid in chronic renal failure, in the case of injured or infected tissues, in the application of the implants to be placed in the body by washing.

PREVIOUS TECHNIQUE

Known as serum, the liquid given through the veins in hospitals, It is called physiological serum. It is a sterile liquid and is used as a treatment tool in various cases. In order to solve the current problem before our invention, in order to prevent the spread of cancer cells after surgery of cancer tissues and to eliminate the existing cancer cells in surrounding tissues, in injured or infected tissues, in the application of implants to be placed in the body, and in the treatment of wound healing positively contribute to the serum physiological BRIEF DESCRIPTION OF THE INVENTION

The invention cancerous tissues of the surgical area after surgery preventing the spread of cancer cells and washed with this liquid, present in cancer cells assist in the destruction of the surrounding tissue, surgery performed, or not performed with the solution of a regular wash the inside of the abdomen with intraabdominal cancer in order to extend the life due to positive contributions to the improvement of tissue debridement of wounds anywhere on the, it is related to the positive contribution of the implants placed in the body to the wound healing by increasing the harmony of the tissue by washing with this liquid and alkalinizing dializate which can be used for the purpose of dialysis in chronic renal diseases and disposable. DETAILED DESCRIPTION OF THE INVENTION

In recent studies, it has been observed that the pH around the cancer tissue and microenvironment proceeds to the acidosis, which means the disruption of the alkali / acid balance, and the resulting acidosis increases the metastasis and progression of the cancer. In order to solve this problem, alkaline dialysate which has a single use has been developed.

During the development of our invention, the changes in the pH of the acid in the fluid formed in the subjects by applying continuous ambulatory peritoneal dialysis (CAPD) to the peritonitis carcinomatosa (PC) induced mice, which are affected by the malignant tumor cells of the peritoneum, by administering dialysis fluid to the abdominal cavity through the alkaline dialysate, oxidative stress, histopathological changes and survival in liver and kidney tissues were investigated. Thus, this fluid was found to be beneficial in cancer tissue and in injured or injured cells.

In the context of the aforementioned experiment, the dialysate with a pH of 7.56 was prepared in accordance with the interstitial fluid, the mice were divided into 4 groups and each subject was formed with Erlich Tumor cells PC. During the following 7 days, the first and third groups were given intraperitoneal (0.03 ml / kg) dialysate. After 7 days following the acid formation, the same groups were given intraperitoneal dialysate by the amount of acid taken by paracentesis once daily until the day of death. The 2nd and 4th groups did not have any treatment. On the ninth day, after taking samples from the 1 st and 2nd group subjects, intra-abdominal fluid was euthanized and the liver and kidney tissues were taken for examination. CAPD was applied to the third group and followed up with the 4th group for survival.

According to the results of this experiment, in the CAPD-treated group-1 , in the intra-abdominal fluid samples according to group-2, the pH levels were higher. As a result of this, p <0.001 , p value less than 0.05 indicates that the finding is meaningful in scientific studies. Considering the increase in TBARS (Thiobarbutyric acid reactive substances) values for the severity of tissue damage, the levels of liver TBARS were lower (p = 0.007) and the tissue had a higher level of reduced reduced glutathione (GSH) (p = 0.003). It was observed.

In Group 1 , connective tissue in liver tissue (p=0.042), granulation tissue (p=0.048), necrotic cells (p=0.031 ), mono nuclear cells (P=0.079) and vascular congestion (p=0.041 ) were less than Group 2. These markers are increased depending on the degree of liver injury. In Group 1 , glomerulde mesengial Matrix discharge( p = 0.003), adhesion in Bowman capsule(0.014), tubular damage and dilatation(p=0.12) was less than Group 2. These markers are increased depending on the degree of kidney injury.

Mean life expectancy and average life span were increased by 10.4% (p <0.001 ) and average life span was 26.1 % in group-3.

As a result of this study, it was shown that the application of CAPD with alkaline dialysate decreased acidification in intraabdominal fluid. It is concluded that it prevents the damage of liver and kidney tissues in the cancerous body and prolongs the life expectancy with the average life expectancy.

For the management of gastrointestinal, gynecological, urological carcinomas with the alkaline dialysate during or after surgery, because of their positive contribution to mortality and morbidity (emergence of different disease states) for intraabdominal cancer surgery, which can be resected surgically (nonoperatively) and non-resectable and in particular a new treatment strategy for PC.

Apart from these uses, the use of implants to be implanted in the body of this solution is suitable for use as implants for dialysis in peritoneal dialysis in the treatment of implants by washing with this liquid and in the treatment of chronic renal failure.

The content of the present solution to our patent application is: in every 1000 ml sterile liquid, at least 124 up to 150 mEq / L Sodium (Na), at least 100 up to 121 mEq / L Chloride (Cl), at least 5 up to 40 mEq / L Bicarbonate (HC03), at least 1.5 up to 3 mEq / L Magnesium (Mg), at least 1.5 up to 3 mEq / L Calcium (Ca), at least 1.5 up to 3 mEq / L Sulfate, at least 0.1 up to the amount of gluconate in 1 ml 10% calcium gluconate ampoule consists of the amount of water (H20). The solution contains at least four of the above-mentioned components in each 1000 ml sterile liquid. The pH of this liquid is at least 7.30 and maximum 7.70.

The best values I have achieved as a result of my work; each 1000 ml of liquid solution contained 144mEq / L Na, 114 mEq / L Cl, 30 mEq / L HC03, 1.83 mEq / L Mg, 2.32 mEq / L Ca, 0.5 ml 10% calcium gluconate, 1.83 mEq / L Sulfate and the rest H20 and 7.56 pH ratio.

Claims

1 . An alkaline dialysate liquid for destroying cancer cells characterized by comprising that in each 1000 ml sterile liquid, at least 124 up to 150 mEq / L Na, at least 100 up to 121 mEq / L Cl, at least 5 up to 40 mEq / L HC03, at least 1.5 up to 3 mEq / L Mg characterized in that it contains at least 1 .5 up to 3 mEq / L Ca, at least 1.5 up to 3 mEq / L Sulfate, at least 0.1 up to 1 ml 10% calcium gluconate and the remaining amount H20.

2. The alkaline dialysate fluid of claim 1 characterized by comprising a pH value of at least 7.30 and a maximum of 7.70.